BioDrugs

, Volume 20, Issue 4, pp 259–262 | Cite as

Spotlight on Trastuzumab in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer

Adis Spotlight

Abstract

Trastuzumab (Herceptin®) is a humanized monoclonal antibody used in the treatment of breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2), which is associated with clinically aggressive disease and a poor prognosis.

The addition of intravenous trastuzumab to first-line chemotherapy improved the time to disease progression, objective response rate, duration of response, and overall survival in randomized, multicenter trials in women with HER2-positive metastatic breast cancer. As such, trastuzumab has become the standard of care in this setting, despite its high acquisition cost and potential for cardiac events, and is licensed for use in combination with paclitaxel (Europe and the US) or docetaxel (Europe). In addition, trastuzumab monotherapy is approved for use in patients with HER2-positive metastatic breast cancer who have previously received chemotherapy for their metastatic disease. Recent data from large phase III trials with trastuzumab in the adjuvant setting revealed significant improvements in disease-free and overall survival. Thus, trastuzumab is also rapidly becoming a standard component of adjuvant therapy for patients with HER2-positive early-stage breast cancer.

References

  1. 1.
    Roche Products Ltd. Herceptin®: summary of product characteristics (annex 1); 2000 Aug 28 [online]. Available from URL: http://www.emea.eu.int/humandocs/PDFs/EPAR/Herceptin/H-278-PI-en.pdf [Accessed 2005 Nov 18]
  2. 2.
    Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992 May; 89: 4285–9PubMedCrossRefGoogle Scholar
  3. 3.
    Albanell J, Codony J, Rovira A, et al. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003; 532: 253–68PubMedCrossRefGoogle Scholar
  4. 4.
    Herceptin® product monograph 2004 update. Basel: F. Hoffmann-La Roche Ltd, 20 04Google Scholar
  5. 5.
    Mohsin SK, Weiss HL, Gutierrez MC, et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005 Apr 10; 23(11): 2460–8PubMedCrossRefGoogle Scholar
  6. 6.
    Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279–80PubMedCrossRefGoogle Scholar
  7. 7.
    Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825–31PubMedGoogle Scholar
  8. 8.
    Pegram MD, Konecny GE, O’Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004 May 19; 96(10): 739–49PubMedCrossRefGoogle Scholar
  9. 9.
    Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002 Mar; 49(3): 211–6PubMedCrossRefGoogle Scholar
  10. 10.
    Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005 Apr 1; 23(10): 2162–71PubMedCrossRefGoogle Scholar
  11. 11.
    Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003 Nov 1; 21(21): 3965–71PubMedCrossRefGoogle Scholar
  12. 12.
    Harris K, Washington CB, Lieberman J-F, et al. A population pharmacokinetic (PK) model for trastuzumab (Herceptin) and implications for clinical dosing [abstract no. 488]. Proc Am Soc Clin Oncol 2002; 21 Pt 1: 123aGoogle Scholar
  13. 13.
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 Mar 15; 344(11): 783–92PubMedCrossRefGoogle Scholar
  14. 14.
    Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003 Jan; 21(1): 46–53PubMedCrossRefGoogle Scholar
  15. 15.
    Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002 Feb 1; 20(3): 719–26PubMedCrossRefGoogle Scholar
  16. 16.
    Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005 Aug; 6(3): 240–6PubMedCrossRefGoogle Scholar
  17. 17.
    Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005 Jul 1; 23(19): 4265–74PubMedCrossRefGoogle Scholar
  18. 18.
    Xu L, Song S, Zhu J, et al. Results of a phase II trial of Herceptin® plus Xeloda® in patients with previously untreated HER2-positive metastatic breast cancer [abstract no. 3049]. Breast Cancer Res Treat 2004; 88Suppl. 1: 128–9. Plus poster presented at the 27th Annual San Antonio Breast Cancer Symposium; 2004 Dec 8–11; San Antonio (TX)Google Scholar
  19. 19.
    Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002 Apr 1; 20(7): 1800–8PubMedCrossRefGoogle Scholar
  20. 20.
    Montemurro F, Choa G, Faggiuolo R, et al. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study. Am J Clin Oncol 2003 Feb; 26(1): 95–7PubMedGoogle Scholar
  21. 21.
    Tedesco KL, Thor AD, Johnson DH, et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 2004 Mar 15; 22(6): 1071–7PubMedCrossRefGoogle Scholar
  22. 22.
    Brufsky AM, Cleary D, Fuchs C, et al. First-line chemotherapy for metastatic breast cancer (MBC) with docetaxel (T), carboplatin (C), and traztuzumab (H): a phase II trial [abstract no. 71]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31–Jun 3; Chicago (IL): 18Google Scholar
  23. 23.
    Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004 May 19; 96(10): 759–69PubMedCrossRefGoogle Scholar
  24. 24.
    Slamon D, Yeon CH, Pienkowski T, et al. Survival analysis from two open-label non-randomized phase II trials of trastuzumab combined with docetaxel and platinums (C, cisplatin or carboplatin) in women with HER2+ advanced breast cancer [abstract no. 642 plus poster]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5–8; New Orleans (LA)Google Scholar
  25. 25.
    Pienkowski T, Fumoleau P, Eiermann W, et al. Taxotere, cisplatin and Herceptin (TCH) in first-line HER2 positive metastatic breast cancer (MBC) patients, a phase II pilot study by the Breast Cancer International Research Group (BCIRG 101) [abstract no. 2030]. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12–15; San Francisco (CA)Google Scholar
  26. 26.
    Yardley D, Greco A, Porter LL, et al. First-line treatment of HER2-positive metastatic breast cancer with trastuzumab, docetaxel and vinorelbine: results of a Minnie Pearl Cancer Research Network trial [abstract no. 146P]. Ann Oncol 2004; 15 Suppl. 3: iii39. Plus poster presented at the 29th European Society of Medical Oncology Congress; 2004 Oct 29–Nov 2; ViennaGoogle Scholar
  27. 27.
    Brufsky A, Orlando M, Fox K, et al. Phase II study of gemcitabine and trastuzumab combination therapy in patients with HER2-overexpressing metastatic breast cancer: first stage results [abstract no. 3047]. Breast Cancer Res Treat 2004; 88 Suppl. 1: S128. Plus poster presented at the 27th San Antonio Breast Cancer Symposium; 2004 Dec 8–11; San Antonio (TX)Google Scholar
  28. 28.
    Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer: a Hellenic Cooperative Oncology Group phase II study. Ann Oncol 2001 Nov; 12: 1545–51PubMedCrossRefGoogle Scholar
  29. 29.
    Gasparini G, Morabito A, De Sio L, et al. Preliminary clinical results of a randomized phase IIb study of weekly pacltiaxel +/− trastuzumab as first-line therapy of patients with HER-2/neu positive metastatic breast cancer [abstract no. 227]. 26th Annual San Antonio Breast Cancer Symposium; 2003 Dec 3–6; San Antonio (TX) [online]. Available from URL: http://www.sabcs.org [Accessed 2003 Dec 3]
  30. 30.
    John M, Hindenburg HJ, Hinke A, et al. Weekly paclitaxel plus trastuzumab in metastatic breast cancer: a multicentre German trial [abstract no. 458]. EJC Supplements 2003 Sep; 1(5): S139–40Google Scholar
  31. 31.
    Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19(10): 2587–95PubMedGoogle Scholar
  32. 32.
    Burris H, Yardley D, Jones S, et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004 May 1; 22(9): 1621–9PubMedCrossRefGoogle Scholar
  33. 33.
    Cortes J, Climent M, Lluch A, et al. Updated results of a phase II study (M77035) of Myocet® combined with weekly Herceptin® and paclitaxel in patients with HER2-positive locally advanced or metastatic breast cancer [abstract no. 3041]. Breast Cancer Res Treat 2004; 88 Suppl. 1: 125–6Google Scholar
  34. 34.
    Bianchi G, Albanell J, Eiermann W, et al. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 2003 Dec 1; 9 (16 Pt 1): 5944–51PubMedGoogle Scholar
  35. 35.
    Colomer R, Mayordomo JI, Calvo L, et al. HER2 ECD-positive metastatic breast cancer treated with gemcitabine, paclitaxel plus trastuzumab [abstract no. 3046]. Breast Cancer Res Treat 2004; 88Suppl. 1: S127–8. Plus poster presented at the 27th Annual San Antonio Breast Cancer Symposium; 2004 Dec 8–11; San Antonio (TX)Google Scholar
  36. 36.
    Fountzilas G, Christodoulou C, Tsavdaridis D, et al. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest 2004; 22(5): 655–62PubMedCrossRefGoogle Scholar
  37. 37.
    Miller KD, Sisk J, Gize G, et al. Phase II study of gemcitabine, paclitaxel and trastuzumab in metastatic breast cancer: a Hoosier Oncology Group trial [abstract no. 437]. 25th Annual San Antonio Breast Cancer Symposium; 2002 Dec 12; San Antonio (TX) [online]. Available from URL: http://www.sabcs.org [Accessed 2003 Feb 10]
  38. 38.
    Bayo-Calero JL, Mayordomo-Camara JI, Sanchez-Rovira P, et al. A multicenter study with trastuzumab and vinorelbine as first and 2nd line treatment in patients with Her2 positive metastatic breast cancer [abstract no. 5069]. Breast Cancer Res Treat 2004; 88Suppl. 1: 207–8Google Scholar
  39. 39.
    Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003 Aug 1; 21(15): 2889–95PubMedCrossRefGoogle Scholar
  40. 40.
    Chan A, Petruzelka L, Untch M, et al. Long term survival of vinorelbine and trastuzumab as first line therapy for HER2-positive metastatic breast cancer patients [abstract no. 587]. J Clin Oncol 2005 Jun 1; 23 (16 Suppl.): 25s. Plus poster presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)Google Scholar
  41. 41.
    de Wit M, Becker K, Thomssen C, et al. Vinorelbine and trastuzumab as first line therapy in patients with HER2-positive metastatic breast cancer: interim analysis of a prospective, open-label, multicentre phase II trial [abstract no. 138P]. Ann Oncol 2004; 15Suppl. 3: iii37Google Scholar
  42. 42.
    Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 2002; 7(5): 410–7PubMedCrossRefGoogle Scholar
  43. 43.
    Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17(9): 2639–48PubMedGoogle Scholar
  44. 44.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005 Oct 20; 353(16): 1659–72PubMedCrossRefGoogle Scholar
  45. 45.
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. 1 2005 Oct 20; 353(16): 1673–84Google Scholar
  46. 46.
    Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [abstract no. 1 plus oral presentation]. 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8–11; San Antonio (TX)Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Adis International LimitedMairangi BayNew Zealand

Personalised recommendations